ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 983 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

    Jing Cui1 and International RA Consortium on Therapy (InteRACT)2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy and Division of Genetics, Boston, MA

    Background/Purpose:  There are no biomarkers that predict response to anti-TNF therapy in rheumatoid arthritis (RA).  Here, we conduct a genome-wide association study (GWAS) to identify…
  • Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting

    Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis

    Claire I. Daien1, Anne-Marie Dupuy Gorce2, Edith Pinot2, Thibault Mura3, Jean-Paul Cristol2, Bernard Combe4 and Jacques Morel5, 1Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 2Biochemistry, Hopital Lapeyronie, Montpellier, France, 3CIC, Hopital Gui De Chauliac, Montpellier, France, 4Rheumatology, Hopital Lapeyronie, Montpellier, France, 5Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

    Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…
  • Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting

    Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients

    Frank Behrens1, Michaela Koehm1, Diamant Thaci2, Brigitte Krummel-Lorenz3, Gerd Greger4, Bianca Wittig4 and Harald Burkhardt5, 1CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, 2Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, 3CIRI/Endokrinologikum, Frankfurt/Main, Germany, 4Abbott GmbH & Co KG, Wiesbaden, Germany, 5CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany

    Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…
  • Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting

    The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania

    Ioan Ancuta1, Catalin Codreanu2, Ruxandra Ionescu3, Magda Parvu4 and Mihai Bojinca1, 1Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 2Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, 3Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania

    Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
  • Abstract Number: 826 • 2012 ACR/ARHP Annual Meeting

    Predictors of Return to Work During 3 Years After Start of First Tumor Necrosis Factor Antagonist in a National Cohort of Biologics-Treated Patients with Rheumatoid Arthritis

    Tor Olofsson1, Ingemar F. Petersson2, Jonas Eriksson3, Martin Englund2, Pierre Geborek1, Lennart T.H. Jacobsson4, Johan Askling5 and Martin Neovius3, 1Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 2Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: To estimate predictors of return to work during 3 years following start of anti-TNF therapy in working-age RA patients with total work disability at…
  • Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting

    Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients

    Mathieu Verdet1, Clément Guillou2, Marie-Laure Potier2, Martine Hiron2, Fabienne Jouen3, Olivier Boyer4, Thierry Lequerré5 and Olivier Vittecoq6, 1Rheumatology, Rouen University Hospital, Bois Guillaume, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 3Immunology, Rouen University Hospital, Rouen Cedex, France, 4Immunology, INSERM U905, University of Rouen, Rouen, France, 5Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 6Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France

    Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
  • Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting

    Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis

    Felicity Buckley1, Axel Finckh2, Thomas W. Huizinga3, Fred Dejonckheere4 and Jeroen P. Jansen1, 1MAPI Consultancy, Boston, MA, 2Rhumatology, University Hospital of Geneva, Geneva, Switzerland, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland

    Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
  • Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting

    Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study

    Désirée van der Heijde1, Jürgen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Endokrinologikum Berlin, Berlin, Germany, 4UCB Pharma, Braine, Belgium, 5UCSD School of Medicine, La Jolla, CA

    Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
  • Abstract Number: 828 • 2012 ACR/ARHP Annual Meeting

    Association between Anti-Tumor Necrosis Factor Therapy and the Risk of Ischemic Stroke in Subjects with Rheumatoid Arthritis. Results From the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA)

    Audrey S. Low1, Mark Lunt2, Louise K. Mercer3, James B. Galloway4, Rebecca Davies5, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium3, Deborah P. Symmons1, William G. Dixon6, Kimme L. Hyrich5 and On behalf of the BSRBR7, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 6The University of Manchester, Manchester, United Kingdom, 7British Society for Rheumatology, London, United Kingdom

    Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) morbidity and mortality, with some studies suggesting an increased risk of stroke…
  • Abstract Number: 433 • 2012 ACR/ARHP Annual Meeting

    Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries

    Marieke J.H. Coenen1, Masha Umicevic-Mirkov2, Hans Scheffer2, Sophine B. Krintel3, Sita H. Vermeulen4, Julia S. Johansen3, Wietske Kievit5, Mart A.F.J. van de Laar6, Piet L.C.M. van Riel5, Barbara Franke2 and Merete L. Hetland7, 1Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3DANBIO and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 4Human Genetics and Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6Department of Rheumatology and DREAM registry, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 7Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: Patients with rheumatoid arthritis (RA)  rate pain relief as the highest priority in treatment outcome, and tumor necrosis factor inhibitors (anti-TNF) have proven very…
  • Abstract Number: 2131 • 2012 ACR/ARHP Annual Meeting

    An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (1986-2011)

    Elena Nikiphorou1, Lewis Carpenter2, Sam Norton3, David James4, Patrick D. Kiely5, David Walsh6, Richard Williams7 and Adam Young3, 1Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, 2Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, 3Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, 4Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom, 5Rheumatology Dept, St. Georges Hospital, London, United Kingdom, 6Academic Rheum/Clin Sci Bldg, City Hospital, Nottingham, United Kingdom, 7Rheumatology, County Hospital, Hereford, United Kingdom

    Background/Purpose: The need for orthopaedic surgery in Rheumatoid Arthritis (RA) is the result of failed medical treatment and a surrogate marker for joint destruction. Reliable…
  • Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting

    Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors

    Yair Molad1 and Shachaf Ofer-Shiber2, 1Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, 2Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel

    Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…
  • Abstract Number: 777 • 2012 ACR/ARHP Annual Meeting

    Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study

    Robert B. M. Landewé1, Martin Rudwaleit2, Désirée van der Heijde3, Maxime Dougados4, Walter P. Maksymowych5, Jürgen Braun6, Atul A. Deodhar7, Christian Stach8, Bengt Hoepken8, Geoffroy Coteur9, Danuta Kielar9, Andreas Fichtner8, Terri Arledge10 and Joachim Sieper11, 1Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 2Endokrinologikum Berlin, Berlin, Germany, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Oregon Health & Science University, Portland, OR, 8UCB Pharma, Monheim am Rheim, Germany, 9UCB Pharma, Brussels, Belgium, 10UCB Pharma, Rtp, NC, 11Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA ) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), as defined by the ASAS criteria.1 RAPID-axSpA (NCT01087762) is the first…
  • Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting

    Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents

    Ioan Ancuta1, Catalin Codreanu2, Ruxandra Ionescu3, Magda Parvu4 and Mihai Bojinca5, 1Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, 2Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, 3Clinic Hospital "Sf. Maria", Bucharest, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, 5Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania

    Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
  • Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting

    Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis

    Josef S. Smolen1, Ronald F. van Vollenhoven2, Andrew S. Koenig3, Ronald Pedersen3, Annette Szumski4 and Eustratios Bananis4, 1Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, 3Specialty Care, Pfizer Inc, Collegeville, PA, 4Specialty Care, Pfizer Inc., Collegeville, PA

    Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology